Carcinoembryonic Antigen (CEA) Market Share, Size, Growth and Dynamics | Forecast To 2028

United States - 26th September 2019: Carcinoembryonic Antigen (CEA) Market is expected to reach USD 2.56 Billion by 2022, which is anticipated to grow at a CAGR of more than 6.6% during the forecast period. The market is expected to witness significant growth in the coming few years owing to various key attributes such as growing incidence of cancer and technological advancement regarding the development of novel biomarkers. According to WHO estimates in 2015, globally cancer is the second leading cause of death with over 8.8 million deaths. On the basis of the Age-Standardized rate of incidence, there are approximately 205 new cases of cancer for every 100,000 men and nearly 165 new cases of cancer for every 100,000 femalesin the world. Carcinoembryonic antigens are the most cost effective technique for the preclinical detection of illness.

Request Sample Copy @ https://www.millioninsights.com/industry-reports/carcinoembryonic-antigen-cea-market/request-sample

Technological advancements pertaining to proteomics, which include protein bioinformatics, mass spectroscopy, protein labelling, imaging, and array based approaches, is one of the crucial factors expected to fuel up the market growth. Development of new biomarkers and various immunological techniques such as radioimmunoassay that can be used with carcinoembryonic antigen (CEA) for detection of various types of cancers, and thus also propel the market growth. For instance, the development of tumor markers, which is used in combination with CEA for detection of colorectal cancer. Favorable government initiatives to introduce new diagnostic tools/technologies is anticipated to boost the market growth. Moreover, rising demand for minimally invasive diagnostic procedures to avoid the various post procedure adverse effects impel the growth of this market.

Application Insights

This segment include key application, namely colorectal, ovarian, pancreatic, breast, thyroid and other cancer applications. In 2016, colorectal cancer dominated the market in terms of revenue share. Rising incidence of colorectal cancer and increase sensitivity to detect the antigen are the factors driving the growth of this segment. According to the American Cancer Society, in the U.S colorectal cancer is the third leading cause of death in women and second in men with nearly 95,520 new cases of colon cancer. Furthermore, increased consumption of alcohol, less physical activity, unhealthy diet, and rapidly changing lifestyle also contribute in the growth of colorectal cancer in the recent years.

Breast cancer is another segment experiencing significant growth owing to the factors such as rising female population above 50 years, advancements in biomarkers and increase in number of patients undertaking hormone replacement therapy (HRT), and breast augmentation & reconstruction surgery. Increasing government initiative coupled with rising consumer awareness for different treatment procedures is also driving the growth of the market. Moreover, other breast related diseases such as infections, lesions, and fibrocysts are also expected to contribute towards the growth in early diagnosis.

Browse Complete Report with TOC @ https://www.millioninsights.com/industry-reports/carcinoembryonic-antigen-cea-market

Carcinoembryonic Antigen Application Outlook (Revenue, USD Million, 2012 - 2022)

        • Colorectal cancer

        • Pancreatic cancer

        • Ovarian cancer

        • Breast cancer

        • Thyroid cancer

        • Others

For More Information, Visit Our Blog @ www.digitalmarket360.wordpress.com